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Abstract Neuroendocrine differentiation has been de-
scribed in rectal adenocarcinomas receiving neoadjuvant
therapy prior to radical surgery, but its clinical relevance is
controversial and no data are currently available in
colorectal carcinoma metastases as compared to primary
tumors. The presence of chromogranin A positive tumor
cells was investigated by means of immunohistochemistry
on surgical specimens from 54 primary colorectal carcino-
mas and their corresponding metastases, resected at
diagnosis or during tumor progression. In 47 patients,
tumor metastases were resected 1 month to 12 years after
chemotherapy and/or radiotherapy, while in the remaining
seven patients no additional therapy after primary surgery
was performed. In primary tumors, neuroendocrine differ-
entiation was found in 12/54 cases (22.2%) as compared to
25/54 metastatic lesions (46.3%; p=0.01). The presence of
neuroendocrine phenotype was not correlated with any
clinical pathological parameter nor with a different prolifera-
tion index. However, patients having neuroendocrine cells in
the primary tumor had a significantly shorter survival from the
time of metastatic spread than those having not (33.3 vs.
55.5 months; p=0.04). In summary, our data show that
colorectal carcinoma metastases contain a higher percentage
of neuroendocrine differentiated cells as compared to their
corresponding primaries, a finding possibly related to the
influence of chemotherapy in neuroendocrine differentiation
during colorectal carcinoma progression.
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Introduction
Neuroendocrine differentiation has been described in
human adenocarcinomas of the prostate, breast, stomach,
lung, and colorectum, among others [1–8]. The clinical
significance of this finding is debated and in any case
differs among the various organs. In the prostate, neuroen-
docrine differentiation has been demonstrated in therapy
naïve cases but it has been specifically associated to
hormone refractory cancers and indeed found associated
to tumor progression and a worse prognosis [5]. At
variance, in breast cancer neuroendocrine differentiation
has been consistently demonstrated to lack any prognostic
significance [9], whereas its association with a more
aggressive disease is still controversial in lung [7, 10] and
stomach carcinomas [6].
In colorectal carcinoma, neuroendocrine cells were
identified in up to 77% of cases, largely depending on the
method used to assess the neuroendocrine cell population
[1, 11, 12]. Classically, chromogranin A immunohisto-
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chemistry is the most common technique, although it is
generally considered that a panel of neuroendocrine
markers, including synaptophysin, CD56 and others, has
to be preferred in order to increase the sensitivity.
Nevertheless, the clinical relevance of neuroendocrine
differentiation in colorectal carcinoma is still debated being
either associated to poor survival [13] or not [11].
The mechanisms leading to neuroendocrine differentiation
in colorectal carcinoma are incompletely understood and are
currently accepted as belonging to divergent differentiation
processes that might be modulated by therapeutic interven-
tions. In fact, Shia et al. [14] described a significant increase
of chromogranin A positive cells in resected rectal adeno-
carcinomas after neo-adjuvant chemotherapy alone or com-
bined to radiotherapy; comparing endoscopic biopsies with
the corresponding rectal surgical specimen, it was shown that
68% of resected rectal carcinomas after chemotherapy had
chromogranin A positive tumor cells, as compared to 30% of
cases in pre-treatment endoscopic biopsies and to 17% of
cases in a control series of conventional, untreated cases.
This observation suggests that pharmacological intervention
may have potential effects on the selection of specific cell
types that are not sensitive (or not as sensitive) to
conventional treatment strategies. This phenomenon is well
known in prostatic adenocarcinoma treated with androgen
deprivation therapy: an increase of chromogranin A immu-
noreactive cells in tumor tissue (in association to raised
chromogranin A serum levels) has been correlated to the
onset of hormonal refractory disease. In addition, the
presence of a neuroendocrine cell component in therapy
naïve prostate cancer patients was found predictive of
androgen deprivation treatment failure [5].
When re-evaluating the morphological features of a
rectal adenocarcinoma that occurred in a young woman that
is following a long disease free survival after complete
resection and medical treatment of a local pelvic recurrence,
we observed a significant increase in the amount of
chromogranin A positive cells in the recurrent pelvic tumor
compared to the primary carcinoma specimen. In between
the two operations, the patient received several courses of
chemotherapy, as described elsewhere [15]. This observa-
tion, in agreement with the data reported by Shia et al. [14],
prompted us to investigate if chemotherapy can also affect
the extent of neuroendocrine differentiation in resected
metastases of relapsing colorectal carcinomas, compared to
their primary tumor. We here show that neuroendocrine
differentiation, as detected by chromogranin A immunore-
activity, is significantly higher in resected pulmonary, liver,
or abdominal metastases of colorectal cancer compared to
the corresponding primaries. In addition, median survival
was shorter for colorectal carcinomas with a neuroendo-
crine differentiated population in the primary tumor,
indicating that the neuroendocrine cell population may
respond differently to current medical treatment for colo-
rectal cancer and may possibly affect survival.
Materials and methods
Patients From the colorectal carcinoma database established
at the Oncology Unit of the San Luigi Hospital and University
of Turin, 54 patients were retrospectively collected in the
period from 1996 to 2008, having a radically resected
colorectal adenocarcinoma and also a resection of a synchro-
nous (21 cases) or metachronous (33 cases) metastasis of the
same tumor, from the lung, liver, or peritoneum. All but seven
patients received adjuvant chemotherapy after resection of the
primary, and eight rectal carcinomas had also radiotherapy
administrated. The chemotherapy protocols administrated to
the 47 patients included oxaliplatin-based chemotherapy
(FOLFOX or XELOX or chronomodulated FFL 4/10 regi-
mens) in 39, irinotecan-based chemotherapy (FOLFIRI) in 2,
and 5-FluoroUracil based chemotherapy (De Gramont’s
schema or protracted continuous infusion of 5FloroUracil) in
six of them.
Tissues Representative paraffin blocks from both primary and
metastatic tumors as well as complete follow-up information
were available for all cases. Metastatic lymph nodes were also
analyzed in 20 cases, as a control group. All pathological
material was anonymized by a pathology staff member not
involved in the current project and tissues from primary and
metastatic tumors of the same patient were coded to allow the
comparison in each anonymized case.
Immunohistochemistry Chromogranin A was selected as a
reliable marker of neuroendocrine differentiation based on
extensive literature data [14], and the immunohistochem-
ical reactions were performed on sections collected onto
charged slides serial to those stained with conventional
hematoxylin and eosin. A standard immunohistochemical
technique was used, including microwave oven antigen
retrieval (15 min in 10 mmol/L citrate buffer solution at
pH 6.0) and incubation with the primary chromogranin A
antibody (clone LK2H10, diluted 1:800; Novocastra
laboratories, Newcastle Upon Tyne, UK). The immuno-
reactions were revealed by a dextran-chain (biotin-free)
detection system (EnVysion, DakoCytomation, Glostrup,
Denmark), using 3,3′-diaminobenzidine (DAB, Dako) as a
chromogen. The slides were then counterstained with
hematoxylin, dehydrated, and mounted. Neuroendocrine
cells of the surrounding colorectal mucosa in primary
tumors served as positive internal control. Sections of
pancreatic islet cells served as external positive controls for
chromogranin A in each immunohistochemical run. Chro-
mogranin A reactivity was scored as reported by Shia [14] in a
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three-tie system, including score 0: no staining in tumor
cells; score 1+: 1–20% of tumor cells stained, and score 2+:
>20% of cells stained. In all cases, the proliferative activity
was assessed by means of Ki-67 immunostaining (clone
MIB1, Dako, diluted 1:300), using the above described
procedure. The proliferative fraction was expressed as
percentage of Ki-67 reactive nuclei, after counting positive
cells out of a thousand. In all cases with a chromogranin A-
positive population, both in primary and metastatic samples,
Ki-67 and chromogranin A were investigated by double
immunohistochemical reactions, using immunoperoxidase
procedure for Ki-67, followed by immunoalkaline phospha-
tase method Envision-AP (Dako) with Vector blue alkaline
phosphatase substrate kit III (from Vector Laboratories, CA,
USA) for chromogranin A, at the same conditions reported
above.
Statistical analysis Differences between chromogranin A
expression and clinical pathological variables were ana-
lyzed by the chi-square test with Yates’ correction, when
appropriate, whereas mean Ki-67 indexes within different
groups were compared using Student’s t test. Survival
curves were plotted using the Kaplan–Meier method and
were statistically evaluated using the log-rank test. These
statistical computations were performed using the SPSS for
Windows and STATISTICA for Windows software. The
significance level was set at p<0.05.
Results
Patients The present case series of 54 cases (Table 1) included
23 females and 31 males having a median age of 60.5 years
(range 28–79). The primary tumors were located in the right
colon (12 cases), left colon (25 cases), and rectum (17 cases).
Conventional adenocarcinoma was observed in 48 cases,
while the remaining six cases were mucinous carcinomas.
With regard to tumor grade, three cases were well differen-
tiated, 40 moderately and 11 poorly differentiated. According
to the 2010 TNM 7th edition staging system, 48 cases were
staged pT3–T4, being the remaining six tumors staged pT1–
T2. Most cases (43/54, 79.6%) had lymph node metastases at
the time of diagnosis. The site of distant metastasis examined
in the present study was liver in 33 patients, peritoneum in 11
patients, lung in nine patients, and ovary in one patient.
Neuroendocrine differentiation Positive chromogranin A
immunostaining, including both scores 1 and 2, was
observed in 12 of the 54 primary colorectal carcinomas
(22.2%) and in 25/54 metastases (46.3%). This difference
Number of patients 54
Median age (years) (range) 60.5 (28–79)
Male/Female ratio 31/23
Primary tumor location R/colon: 12, L/colon: 25,
Rectum: 17
Tumor grade G1: 3, G2: 40, G3: 11
Tumor stage T1: 1, T2: 5, T3: 37, T4: 11;
N0: 11, N1-2: 43
Surgically resected metastasis Liver: 33, Lung: 9, Peritoneal: 11,
Ovarian: 1
Chemotherapy administrated 47
No chemotherapy administrated 7 (5 at diagnosis and 2 during
tumor progression)
Chromogranin A expression 12/54 (22.2%) in primary CRC
25/54 (46.3%) in CRC metastases
Chi-square p=0.01
Ki-67 proliferation index 67.1% (primary CRC) and
62.4% (metastases)
Median survival from first
diagnosis
CgA negative in primary CRC 59.9 months (42 pats)




CgA negative in primary CRC 55.5 months (42 pats)
CgA positive in primary CRC 33.3 months (12 pats)
Log rank p=0.04
CgA negative in CRC metastasis 53.8 months (29 pats)
CgA positive in CRC metastasis 38.3 months (25 pats)
Log rank p=0.18
Table 1 Clinico-pathological
data of 54 colorectal carcinomas
that underwent surgical
resection of a metastasis at
diagnosis or along tumor
progression
R right, L left, CRC
colorectal carcinoma, CgA
chromogranin A
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was statistically significant (p=0.01 by chi-square test). In
primary colorectal carcinomas, chromogranin A-positive
cases were equally distributed between those with synchro-
nous metastases (six cases, 26.3%) and those that devel-
oped metastases at follow up (the other six, 20%).
When comparing chromogranin A staining between
primary tumor and metastasis of the same patient, in 37
cases (68.5%) we failed to show any change (27 double
negative and ten double positive, without any increase in
the extent of positivity in the latter group), whereas an
increase was evident in 15/54 (27.8%), including 13/47
chemotherapy-treated, and 2/7 chemo-naïve patients. In ten of
these 15 cases, the chromogranin A-positive population was
detected in the metastatic tissue only (Fig. 1a–b), whereas in
the remaining five it was already focally present in the
primary tumor (immunohistochemical score 1) but was
increased in the metastasis (immunohistochemical score 2;
Fig. 1c–d). The remaining two cases could not be analyzed
due to the presence of extensive mucin lakes with very few
neoplastic cells in the metastases. Synchronous metastatic
lymph nodes were analyzed in 20 cases, from one to three
metastatic lymph nodes for each case. Among these, ten cases
corresponded to chromogranin A positive and ten cases to
chromogranin A negative primary tumors. All lymph node
samples showed no chromogranin A immunoreactivity, except
for two cases (both having a positive chromogranin A in the
primary tumor, score 1) with rare scattered positive cells.
The presence of neuroendocrine-differentiated primary
colorectal cancers was associated to shorter overall survival
(35.9 versus 59.9 months) and shorter survival from the time
ofmetastatic spread (33.3 versus 55.5months), being the latter
statistically significant in univariate analysis (log rank p=
0.04; Fig. 2); a similar trend was observed considering those
cases having chromogranin A positive cells in the metastases
as opposed to negative cases (38.3 versus 53.8 months from
the time of metastatic spread; log rank p=0.18).
Fig. 1 Primary rectal adenocarcinoma (a, case 4) with no evidence of
neuroendocrine differentiation (normal colonic mucosa in the left).
After 18 months and following 5-FU treatment, a liver metastasis
eventually developed (b), showing numerous scattered neuroendocrine
cells (score 2). Primary colonic adenocarcinoma (c, case 18), with
focal neuroendocrine differentiation (score 1), with subsequent
(9 months later) extensively necrotic liver metastasis (d), following
5-FU and oxaliplatin treatment, showing diffuse neuroendocrine
differentiation (score 2; normal liver in the upper left corner). Double
immunostaining for chromogranin A (blue) and Ki-67 (brown) in a
primary colonic adenocarcinoma (e) and in a liver metastasis (f)
showing numerous proliferating tumor cells and few neuroendocrine
cells in a resting phase (a–d chromogranin A staining, immunoper-
oxidase; e and f double sequential immunoperoxidase for Ki-67 and
immunoalkaline phosphatase for chromogranin A; original magnifi-
cations a and d 100×; b and c 200×; e and f 400×)
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The proliferative activity was assessed by means of Ki-
67 immunostaining in all cases of colorectal carcinoma,
both in the primary and in the metastatic locations (means
67.1% and 62.4%, respectively). No statistically significant
difference was observed between the mean Ki-67 proliferative
index of colorectal carcinomas with neuroendocrine differen-
tiation and negative cancers (78.5% versus 64%, respective-
ly). The proliferative activity of metastatic tissues was also
similar in neuroendocrine and non- neuroendocrine differen-
tiated tumor groups (Ki-67 index of 59.1% and 65.3%,
respectively). Double immunostainings combining chromog-
ranin A and Ki-67 showed that the neuroendocrine cell
population generally was not actively proliferating, both in
primary tumors and metastases (Fig. 1e–f).
When the presence of neuroendocrine differentiation was
compared with primary tumor location (right and left colon
and rectum), tumor histotype (conventional versus mucinous),
tumor stage and grade of differentiation, site of metastasis
(liver versus peritoneum and lung), and response to chemo-
therapy (stable disease versus partial or complete response),
no significant correlation was observed between any of the
above considered parameters and chromogranin A expression,
neither in primary nor in metastatic specimens.
Discussion
In this study, we have shown that distant metastases of
colorectal carcinoma contain a significantly higher amount
of neuroendocrine cells compared to the corresponding
primary tumors, as detected by chromogranin A immunos-
taining in surgical specimens. This may be part of the
natural history of colorectal cancer progression or be related
to the effects of chemotherapy, which generally preceded
the surgical removal of distant metastases.
Since it is virtually impossible to analyze a control group of
surgically resected colorectal carcinomas with no subsequent
chemotherapy (only seven cases were recruited in the current
series), the demonstration of a direct effect of chemotherapy
on the increase of neuroendocrine cells is not possible.
However, this was already demonstrated in a study on rectal
adenocarcinoma preoperatively treated by chemo and/or
radiotherapy [14]. The authors restricted their analysis to
primary tumors, comparing the neuroendocrine cell density
in pre-treatment biopsies versus the corresponding surgical
specimen of rectal cancer, and found a significantly higher
amount of neuroendocrine cells in treated rectal carcinomas
compared to the control group of adenocarcinomas that did
not undergo neoadjuvant therapy.
Based on this report, we therefore expanded the analysis
to colonic and rectal carcinomas and to their metastatic
locations, which are now increasingly being resected
especially from lung and liver, to assess the phenotypic
profile of cancer cell populations in the setting of metastatic
and progressing disease. Indeed, distant metastases were
found to contain a higher amount of neuroendocrine cells,
as compared to their primaries, and this may be the result of
relative selection of tumor clones not responsive to
conventional chemotherapy protocols, or to direct effects
of chemotherapy agents on a fraction of neoplastic cells
differentiated along the neuroendocrine lineage. Moreover,
we analyzed synchronous metastatic lymph nodes in 20
cases, both from chromogranin A negative and positive
primaries, and failed to demonstrate any significant chro-
mogranin A immunoreactivity. Although the limited bulk of
tumor tissue in lymph nodes as compared to primaries or
distant metastases might be a bias, this finding seems to
suggest that the selection of neuroendocrine tumor cell
clones is more likely related to anti-neoplastic treatments
rather than to metastatic progression.
The role of chemotherapy in favoring the increase and
the selection of neuroendocrine differentiated neoplastic
cell clones is controversial. Shia et al. [14] demonstrated a
role of neoadjuvant treatments in inducing a significant
increase of the neuroendocrine cell population in primary
colorectal carcinoma specimens. The same may well be the
case in metastatic locations, although a statistical validation
of this event is currently not possible. The very few cases
(seven) that did not (or could not) undergo chemotherapy
had a variable amount of neuroendocrine cells in their
metastases, but the extremely limited number of cases
hampers any statistical analysis and definite conclusion. In
addition, in some cases, the development of distant
metastases occurred many years after surgery and subse-
quent chemotherapy, suggesting that the different tumor cell
populations, exocrine (mucinous), and neuroendocrine may
Fig. 2 Survival of colorectal carcinoma patients from the time of
metastatic progression, grouped according to chromogranin A reac-
tivity (positivity including immunohistochemical scores 1 and 2) in
the primary tumors (log rank test, p=0.04)
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play complex reciprocal interactions. In this respect, the
expression of transcription factors known to drive neuro-
endocrine differentiation in the embryonic life, such as
human achaete-scute-homologue type 1 (hASH1) may be
involved in the occurrence of neuroendocrine differentia-
tion [16]. Unfortunately, in the present series, no hASH1
expression was observed (data not shown) suggesting that
at least in the intestinal area, the development of neuroen-
docrine differentiated cells may follow alternative path-
ways, compared to other models such as the prostate [17].
In this context, it is of interest that the neuroendocrine
population both in primary tumors and metastases showed a
very low proliferative activity, in agreement with earlier
observations in gastric carcinoma [18] that pointed out that
neuroendocrine cells are terminally differentiated cells,
devoid of any proliferative potential. Moreover, in our
cases, the mean Ki-67 proliferation index was similar in
primary and metastatic cancers, as well as in colorectal
carcinomas with or without neuroendocrine features.
A second issue is related to the prognostic influence of
neuroendocrine differentiation in colorectal carcinoma. In the
present series, cases having a neuroendocrine differentiated
component in the primary tumors had a slightly shorter
survival both from the time of diagnosis and the time from
metastatic spread but statistical significance was reached for
the latter case only, possible due to the relatively small sample
size. Other literature data are in line with this observation
[13, 19, 20], although some authors found no prognostic
differences between neuroendocrine differentiated and
conventional colorectal carcinoma [21]. No correlation
was also observed with any clinical pathological parameter.
In conclusion, we herein reported an increased detection
on neuroendocrine tumor cells in metastatic tissues of
chemotherapy-treated colorectal cancer patients, as compared
to the corresponding primary tumors, associated to reduced
patients’ survival; the biological and predictive meaning of
this observation would deserve further elucidation but is
possibly related to the positive selection by chemotherapy of
neuroendocrine tumors clones that are characterized by a
very low proliferative activity.
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